Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Evaluation of aerosol drug delivery with concurrent low and high flow nasal oxygen

Barry Murphy, Marc Mac Giolla Eain, Mary Joyce, James B. Fink, Ronan MacLoughlin
ERJ Open Research 2022; DOI: 10.1183/23120541.00220-2022
Barry Murphy
1Research and Development, Science & Emerging Technologies, Aerogen Limited, Galway Business Park, Galway , Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Mac Giolla Eain
1Research and Development, Science & Emerging Technologies, Aerogen Limited, Galway Business Park, Galway , Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marc Mac Giolla Eain
Mary Joyce
1Research and Development, Science & Emerging Technologies, Aerogen Limited, Galway Business Park, Galway , Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James B. Fink
2Aerogen Pharma Corporation, , San Mateo, CA , USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for James B. Fink
Ronan MacLoughlin
1Research and Development, Science & Emerging Technologies, Aerogen Limited, Galway Business Park, Galway , Ireland
3School of Pharmacy & Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin , Ireland
4School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin , Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: RMacLoughlin@aerogen.com
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Question addressed by study Administration of aerosol to patients receiving high flow nasal oxygen (HFNO) ranges from concurrent aerosol delivery by mouthpiece to aerosol via cannula alone. This study examines the conditions to provide optimal aerosol delivery with low or high flow nasal oxygen with concurrent mouthpiece or through nasal cannula alone, and the impact on fugitive aerosols.

Materials and Methods A vibrating mesh nebulizer delivered salbutamol via mouthpiece, aerosol holding chamber and nasal cannula to an adult head model simulating relaxed breathing. The inhaled dose (%) (mean±sd) was assayed from a filter distal to the trachea. Optical particle sizers were used to measure fugitive aerosol concentrations during aerosol delivery.

Results Concurrent low flow nasal oxygen (LFNO) and aerosol delivery with a mouthpiece and aerosol holding chamber increased the inhaled dose (%) available, 31.44±1.33% when supplemented with 2 LPM of nasal oxygen. Concurrent HFNO above 30 LPM resulted in a lower inhaled dose (%) compared to aerosol delivered through HFNO alone. The addition of concurrent low or high flow nasal oxygen resulted in no increase in aerosol levels in the test room.

Answer to question posed Concurrent low flow nasal oxygen with a mouthpiece and aerosol holding chamber is an effective and safe means of aerosol delivery.

Footnotes

This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.

This is a PDF-only article. Please click on the PDF link above to read it.

  • Received May 9, 2022.
  • Accepted July 15, 2022.
  • Copyright ©The authors 2022
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

PreviousNext
Back to top
Vol 8 Issue 3 Table of Contents
ERJ Open Research: 8 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation of aerosol drug delivery with concurrent low and high flow nasal oxygen
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Evaluation of aerosol drug delivery with concurrent low and high flow nasal oxygen
Barry Murphy, Marc Mac Giolla Eain, Mary Joyce, James B. Fink, Ronan MacLoughlin
ERJ Open Research Jan 2022, 00220-2022; DOI: 10.1183/23120541.00220-2022

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Evaluation of aerosol drug delivery with concurrent low and high flow nasal oxygen
Barry Murphy, Marc Mac Giolla Eain, Mary Joyce, James B. Fink, Ronan MacLoughlin
ERJ Open Research Jan 2022, 00220-2022; DOI: 10.1183/23120541.00220-2022
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Haemodynamic effects of initial combination therapy in pulmonary arterial hypertension: a systematic review and meta-analysis
  • Analysis of real-world data and a mouse model indicates that pirfenidone causes pellagra
  • Functional clinical impairments and frailty in interstitial lung diseases patients
Show more Original research article

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2022 by the European Respiratory Society